Zhen Su: Excited to announce our second clinical trial of the START clinical Program
Zhen Su, CEO at Marengo Therapeutics, shared a post on LinkedIn:
“Building on the strong momentum of STARt001 Phase 1/2 trial which demonstrated Invikafusp alfa single agent activity in PD-1 resistant solid tumors including MSS CRC and PD-1 negative NSCLC, we are excited to announce our second clinical trial of the START clinical Program, START002 Phase Ib/II clinical investigation of Invikafusp, a first-in-class dual T cell agonist in combination with Trodelvy for breast cancer patients (both HR+/HER2- & TNBC)! We know it is challenge to develop immunotherapy for breast cancer… but we are fully committed to do it and with “the Speed of Oncology” simply because patients wants, needs and deserves new treatment options!
A special thanks to our amazing START-002 investigator team: Steven Isakoff, Erika Hamilton, Aditya Bardia, Philippe Bedard, Virginia Kaklamani.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023